| Ms Carrie R Jordan, CRNA | |
|
7365 Main St Ste 310, Stratford, CT 06614-1300 | |
| (203) 384-3174 | |
| (203) 384-4619 |
| Full Name | Ms Carrie R Jordan |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 20 Years |
| Location | 7365 Main St Ste 310, Stratford, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588672331 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | APRN003213 (Connecticut) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Yale University | 9436061736 | 2241 |
News Archive
Today, the U.S. Food and Drug Administration approved Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three monoclonal antibodies, as the first FDA-approved treatment for Zaire ebolavirus (Ebola virus) infection in adult and pediatric patients.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, Inc., has been granted orphan-drug designation by the U.S. Food and Drug Administration for perifosine, Aeterna Zentaris' novel, potentially first-in-class, oral Akt inhibitor, for the treatment of neuroblastoma.
The Oregon National Primate Research Center and the Oregon Health & Science University School of Medicine have been named to a national team of institutions hoping to preserve or restore fertility in women battling cancer.
Othello Community Hospital, an Inland Northwest Health Services (INHS)-networked facility, has been recognized by the Healthcare Information and Management Systems Society (HIMSS) Analytics as achieving Stage 6 on the EMR Adoption Modelsm (EMRAM). Othello is only the second critical access hospital in the nation to receive this distinction, a testament to its commitment to using technology to best serve patients.
Working with human breast cancer cells and mice, researchers at Johns Hopkins say they have identified a biochemical pathway that triggers the regrowth of breast cancer stem cells after chemotherapy.
› Verified 7 days ago
| Entity Name | Yale University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205822236 PECOS PAC ID: 9436061736 Enrollment ID: O20031105000015 |
News Archive
Today, the U.S. Food and Drug Administration approved Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three monoclonal antibodies, as the first FDA-approved treatment for Zaire ebolavirus (Ebola virus) infection in adult and pediatric patients.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, Inc., has been granted orphan-drug designation by the U.S. Food and Drug Administration for perifosine, Aeterna Zentaris' novel, potentially first-in-class, oral Akt inhibitor, for the treatment of neuroblastoma.
The Oregon National Primate Research Center and the Oregon Health & Science University School of Medicine have been named to a national team of institutions hoping to preserve or restore fertility in women battling cancer.
Othello Community Hospital, an Inland Northwest Health Services (INHS)-networked facility, has been recognized by the Healthcare Information and Management Systems Society (HIMSS) Analytics as achieving Stage 6 on the EMR Adoption Modelsm (EMRAM). Othello is only the second critical access hospital in the nation to receive this distinction, a testament to its commitment to using technology to best serve patients.
Working with human breast cancer cells and mice, researchers at Johns Hopkins say they have identified a biochemical pathway that triggers the regrowth of breast cancer stem cells after chemotherapy.
› Verified 7 days ago
| Entity Name | Bridgeport Anesthesia Associates, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174549257 PECOS PAC ID: 7113824616 Enrollment ID: O20031215000038 |
News Archive
Today, the U.S. Food and Drug Administration approved Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three monoclonal antibodies, as the first FDA-approved treatment for Zaire ebolavirus (Ebola virus) infection in adult and pediatric patients.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, Inc., has been granted orphan-drug designation by the U.S. Food and Drug Administration for perifosine, Aeterna Zentaris' novel, potentially first-in-class, oral Akt inhibitor, for the treatment of neuroblastoma.
The Oregon National Primate Research Center and the Oregon Health & Science University School of Medicine have been named to a national team of institutions hoping to preserve or restore fertility in women battling cancer.
Othello Community Hospital, an Inland Northwest Health Services (INHS)-networked facility, has been recognized by the Healthcare Information and Management Systems Society (HIMSS) Analytics as achieving Stage 6 on the EMR Adoption Modelsm (EMRAM). Othello is only the second critical access hospital in the nation to receive this distinction, a testament to its commitment to using technology to best serve patients.
Working with human breast cancer cells and mice, researchers at Johns Hopkins say they have identified a biochemical pathway that triggers the regrowth of breast cancer stem cells after chemotherapy.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Carrie R Jordan, CRNA 5 Rose Lane, North Branford, CT 06471 Ph: (203) 483-9124 | Ms Carrie R Jordan, CRNA 7365 Main St Ste 310, Stratford, CT 06614-1300 Ph: (203) 384-3174 |
News Archive
Today, the U.S. Food and Drug Administration approved Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three monoclonal antibodies, as the first FDA-approved treatment for Zaire ebolavirus (Ebola virus) infection in adult and pediatric patients.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, Inc., has been granted orphan-drug designation by the U.S. Food and Drug Administration for perifosine, Aeterna Zentaris' novel, potentially first-in-class, oral Akt inhibitor, for the treatment of neuroblastoma.
The Oregon National Primate Research Center and the Oregon Health & Science University School of Medicine have been named to a national team of institutions hoping to preserve or restore fertility in women battling cancer.
Othello Community Hospital, an Inland Northwest Health Services (INHS)-networked facility, has been recognized by the Healthcare Information and Management Systems Society (HIMSS) Analytics as achieving Stage 6 on the EMR Adoption Modelsm (EMRAM). Othello is only the second critical access hospital in the nation to receive this distinction, a testament to its commitment to using technology to best serve patients.
Working with human breast cancer cells and mice, researchers at Johns Hopkins say they have identified a biochemical pathway that triggers the regrowth of breast cancer stem cells after chemotherapy.
› Verified 7 days ago
Meghan Leary, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 7365 Main St, Suite 310, Stratford, CT 06614 Phone: 800-586-2153 |